Molecular basis for sunitinib efficacy and future clinical development |
| |
Authors: | Faivre Sandrine Demetri George Sargent William Raymond Eric |
| |
Institution: | Service Inter-Hospitalier de Cancérologie (SIHC) Beaujon-Bichat and RayLab, H?pital Beaujon, APHP and Denis Diderot University, 100 Boulevard du Général Leclerc, 92118 Clichy Cedex, France. |
| |
Abstract: | Sunitinib malate (SU11248/Sutent; Pfizer) is a multitargeted tyrosine kinase inhibitor that has potent anti-angiogenic and antitumour activities. Definitive efficacy has been demonstrated in advanced renal cell carcinoma and in gastrointestinal stromal tumours that are refractory or intolerant to imatinib (Gleevec; Novartis), which has provided the basis for the recent regulatory approvals for these indications. This article summarizes the discovery and development of sunitinib, and discusses key issues for the multitargeted approach in cancer treatment, such as markers of response and development of resistance, and their significance for the future development of sunitinib and other multikinase inhibitors. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|